Ionis Pharmaceuticals, Inc.

IONS Healthcare Biotechnology

Ionis Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $943.7 million, up 33.8% from fiscal 2024.

Revenue
−40.7%
EPS
−188.5%
Free cash flow
+299.3%
Total debt
+116.0%

Quarter to June 2026, against a year earlier

39.48 0.68 +1.75%
Market cap
$6.5B
P/E
0.0×
Fwd P/E
−12.2×
Dividend yield
—
F-score
4/9
Altman Z
2.12
Beneish M
−3.13
Dividend safety
n/a

Ionis Pharmaceuticals, Inc. 8-K filed Apr 21, 2026

Period ended Apr 21, 2026 · Filed · accepted 7:00 AM ET · Document on sec.gov · Filing index

7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov